James, ND;
Sydes, MR;
Clarke, NW;
Parmar, MKB;
Ritchie, ASWR;
(2016)
Response to ‘High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice’, by Tanguay et al.
Clinical Oncology
, 28
(10)
pp. 666-667.
10.1016/j.clon.2016.07.004.
Preview |
Text
responses_Tanguay_2016_06_22_v2.pdf - Accepted Version Download (285kB) | Preview |
Abstract
Madam — Tanguay and colleagues presented data on patients treated with docetaxel [1]. We agree that the reported rates of neutropenia-based toxicities vary across the trials, as do the categories against which toxicities are reported.
Archive Staff Only
 |
View Item |
